'Cobra Venom' Painkiller Co. Inks Deal To Settle SEC Claims

By Emilie Ruscoe · March 15, 2024, 6:47 PM EDT

A penny stock company that previously held itself out as a maker of cobra venom-infused pain drugs has agreed to resolve U.S. Securities and Exchange Commission fraud claims, according to court...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

Securities and Exchange Commission v. Nutra Pharma Corporation et al

Case Number

Court

New York Eastern

Nature of Suit

Securities/Commodities

Date Filed

September 28, 2018

Recent Articles By Emilie

May 14, 2024
Vein Tech Maker Faces Investor Suit Over DOJ Kickback Probe
April 19, 2024
AI Health Data Co. Faces Investor Suit Over Accounting Issues
April 18, 2024
Doximity Faces Investor Suit Over Slashed Revenue Hopes
February 21, 2024
Former Exec Convicted Of Medtronic Insider Trading Scheme
February 12, 2024
Investors Win Class Cert. Against Failed COVID Test Maker
January 22, 2024
Investors Sue Biopharma Co. After Clinical Trial Data Toss
December 19, 2023
Acadia Investor Says Officers Overhyped Drug's Prospects
December 06, 2023
Cancer Test Co. Overpromised Insurer Coverage, Suit Says
November 27, 2023
Levi, Pomerantz Seek To Lead Insulin Pump Co. Investor Suit
October 03, 2023
Pomerantz Plucks $5.5M Fee For Clover Health Investor Deal